On the stock market since 2021, it operates in the world of health and science. It has 34 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 34% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 89% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 31% a year on average.
Sales run at $12.0M a year. A small number, but proof the product has real buyers.
There is $76.6M in the vault; even if every debt were paid off, $71.3M would remain.
A loss of $25.1M against $12.0M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, LVTX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: LVTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.